NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) or PetCo (WOOF) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally rec ...

SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 16, 2025, Sarepta Therapeutics (NASDAQ: SRPT) announced a major restructuring that involves, in part, a 36% workforce reduction (500 employees) and other steps to annually save about $400 million. The company also agreed with the FDA to include a black box warning of acute liver injury and acute liver failure in Sarepta’s ELEVIDYS label. ELEVIDYS is the company’s gene therapy drug intended to treat a limited category of people with Duchenne muscular d ...

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/sarepta-lawsuit-submission-f ...

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

港股市场表现 - 中国生物制药(1177.HK)早盘涨超3%，因全资附属公司礼新医药与默沙东就PD-1/VEGF双抗LM-299/MK-2010合作进展顺利，近期将收到3亿美元技术转移里程碑付款 [1] - 石药集团(1093.HK)涨超5%，宣布与Madrigal Pharmaceuticals就口服小分子GLP-1受体激动剂SYH2086达成全球独家授权协议 [1] - 有赞(8083.HK)涨超7%，预计上半年收益7.09-7.19亿元人民币(同比+3.3%-4.8%)，净利润6800-7400万元人民币(去年同期亏损429.5万元) [1] - 兴证国际(6058.HK)再涨近18%，因兴业银行提出拥抱科技变革，研究稳定币和人工智能+等数字化战略 [2] - 新东方-S(9901.HK)跌近4%，2025财年Q4净营收12.43亿美元(同比+9.4%)，净利润710万美元(同比-73.7%) [2] - 港股博彩股逆势上涨，美高梅中国(2282.HK)涨超4%，麦格理上调2025年澳门博彩收入预估5%至2357亿元(同比+4%) [3] - 港股黄金股持续走低，潼关黄金(0340.HK)跌超9%，现货黄金一度跌破3270美元/盎司 [4] - 康方生物(9926.HK)涨近5%，其PD-1/VEGF双抗新药依沃西联合多西他赛治疗非小细胞肺癌的III期临床完成首例患者给药 [4] - 伟仕佳杰(0856.HK)涨超3%，2024年东南亚业务收入占比增至74%，净利润占比约51% [5] 美股市场表现 - Meta(META.US)盘后涨超11%，营收超预期并上调全年资本支出下限 [6] - 微软(MSFT.US)盘后涨超8%，云业务营收增长18%，Azure全年收入增34% [6] - Wingstop(WING.US)涨26.85%，Q2调整后每股收益1.00美元(去年同期0.93美元) [6] - 新能源车股走低，蔚来(NIO.US)跌4.25%，特斯拉(TSLA.US)与LG新能源签署43亿美元LFP电池采购协议 [6] - 泰瑞达(TER.US)大涨18.88%，Q2半导体测试设备销售强劲 [6] - 生物制药公司股价飙升，Replimune(REPL.US)涨101.33%，因FDA生物制品评估与研究中心主任离职可能缓解监管压力 [7] - 迈威尔科技(MRVL.US)涨7.07%，与Rebellions合作开发AI系统 [7] - Astera Labs(ALAB.US)涨8.83%，摩根士丹利上调目标价至125美元 [7] - Palo Alto Networks(PANW.US)跌5.58%，拟以约250亿美元收购CyberArk Software [8] - 诺和诺德(NVO.US)跌7.25%，预计2025年营收和利润双双下滑 [8] - Hims & Hers Health(HIMS.US)涨8.73%，预计Q2营收5.52亿美元(同比+74.89%) [8] - 核电板块走高，Oklo Inc(OKLO.US)涨6.51% [8]

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sarepta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

公司股价暴跌 - Sarepta Therapeutics股价在2025年7月18日暴跌7.89美元（跌幅36%）[1] - 股价下跌原因是公司报告第三例患者在接受实验性基因疗法治疗后死亡[1] 证券集体诉讼 - 诉讼案件Dolgicer v Sarepta Therapeutics代表在2023年6月22日至2025年6月24日期间购买公司证券的投资者[2] - 诉讼指控公司关于基因疗法ELEVIDYS的安全性和有效性披露存在问题[4] - 诉讼称公司误导投资者认为ELEVIDYS是安全的且可扩大适用范围[4] 安全事件时间线 - 2025年3月18日公司披露首例接受ELEVIDYS治疗的非行走患者死亡[5] - 2025年4月4日欧盟成员国要求独立数据监测委员会审查死亡事件 公司暂停部分临床试验招募和给药[6] - 2025年6月15日第二例非行走患者因急性肝衰竭死亡 公司暂停向非行走患者发货并停止一项临床试验给药[7] - 2025年6月24日FDA宣布收到两例死亡报告并启动对ELEVIDYS治疗相关急性肝衰竭风险的调查[8] 最新进展 - 2025年7月18日媒体报道6月发生第三例死亡事件 涉及另一种实验性基因疗法SRP-9004[9] - FDA对Sarepta的肢带型肌营养不良基因疗法临床试验实施临床暂停[10] - H_C Wainwright将Sarepta目标股价下调至0美元[10] 调查重点 - 调查公司是否在基因疗法安全性和未来收入潜力方面误导投资者[11] - 调查涉及ELEVIDYS试验方案未能检测到严重副作用以及不良事件严重程度导致试验暂停等问题[9]

生物制药公司股价异动 - Replimune(REPL US)股价飙升逾85% [1] - Sarepta Therapeutics(SRPT US)股价上涨超16% [1] - Capricor Therapeutics(CAPR US)股价大涨超18% [1] 监管人事变动影响 - 美国FDA生物制品评估与研究中心主任普拉萨德上任不到三个月后离职 [1] - 离职正值FDA对多款基因疗法和疫苗采取严格监管措施 [1] 市场解读 - 分析人士认为主任离任可能缓解基因疗法和疫苗企业的监管压力 [1] - 该人事变动被视为基因疗法和疫苗企业的利好消息 [1]

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...